Cor Vasa 2016, 58(6):e631-e635 | DOI: 10.1016/j.crvasa.2016.09.006

High residual platelet reactivity - Does the problem persist even with new antiplatelet drugs?

Martin Hajšl^a,*, Pavel Sedloň^a, Miroslav Zavoral^b, Martin Malý^a

^a Kardiologické oddělení, Interní klinika, 1. lékařská fakulta Univezity Karlovy a Ústřední vojenská nemocnice - Vojenská fakultní nemocnice, Praha, Česká republika

^b Interní klinika, 1. lékařská fakulta Univezity Karlovy a Ústřední vojenská nemocnice - Vojenská fakultní nemocnice, Praha, Česká republika

High residual platelet reactivity (HRPR) in patients taking dual antiplatelet therapy (DAPT) is closely associated with serious ischaemic events, particularly in-stent thrombosis. Literature reports many cases of patients taking the combination of acetylsalicylic acid and clopidogrel with early in-stent thrombosis and the detection of high residual platelet reactivity, but cases in patients using a combination of new antiplatelet drugs are rare. The following case report presents the case of a patient with early in-stent thrombosis in whom HRPR was detected while he was on prasugrel therapy and describes the subsequent management of the complication.

Keywords: Acute coronary syndrome; High residual platelet reactivity; In-stent thrombosis; Prasugrel; Ticagrelor

Received: February 9, 2016; Revised: September 14, 2016; Accepted: September 15, 2016; Published: December 1, 2016  Show citation